STOCK TITAN

Nautilus Biotechnology Inc SEC Filings

NAUT NASDAQ

Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Nautilus Biotechnology filings document SEC reporting for a Nasdaq-listed life sciences tools company developing single-molecule proteome analysis technology. Recent Form 8-K reports furnish quarterly and annual financial results and record material events, including continued-listing compliance with Nasdaq rules.

Proxy materials cover annual meeting procedures, director elections, stockholder voting matters, and board governance. The filings also identify the company's registered common stock under ticker NAUT and provide formal records of its capital structure, governance actions, and public-company reporting obligations.

Rhea-AI Summary

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed Amendment No. 4 to Schedule 13D for Nautilus Biotechnology, Inc. (NAUT) on 24 June 2025. The filing discloses that the reporting group continues to hold 12,815,113 common shares, equal to 10.1 % of NAUT’s 126,148,469 shares outstanding as reported in the company’s 29 April 2025 proxy statement. The position is held on a shared voting and dispositive basis; none of the reporting persons has sole power over the shares.

The stake includes 220,902 shares underlying stock options granted to Michael Altman, a Perceptive Managing Director whose related director compensation is offset against Master Fund fees. Importantly, Mr. Altman ceased serving on Nautilus’s board effective 20 June 2025 when his term expired and he did not stand for re-election. No changes to share ownership levels were reported in this amendment—its primary purpose is to reflect the board-service change and update ownership calculations to the latest outstanding-share figure.

Key takeaways for investors:

  • The Perceptive group remains a double-digit owner, preserving potential influence through its economic stake even after losing direct board representation.
  • The departure of Perceptive’s board designee may reduce the group’s informational access and governance leverage.
  • No purchase or sale of NAUT shares is disclosed; percentages changed only because the outstanding-share count was updated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

How many Nautilus Biotechnology (NAUT) SEC filings are available on StockTitan?

StockTitan tracks 32 SEC filings for Nautilus Biotechnology (NAUT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Nautilus Biotechnology (NAUT)?

The most recent SEC filing for Nautilus Biotechnology (NAUT) was filed on June 24, 2025.